 |
MAP Pharmaceuticals Reports Positive Phase 2 Results for its Inhaled Migraine Drug Candidate
Mar 1, 2007
|
7.8 KB |
|
| |
MOUNTAIN VIEW, Calif., March 1 /PRNewswire/ -- MAP Pharmaceuticals,
Inc. announced today that its Tempo(TM) Migraine drug candidate
met its primary endpoints in a Phase 2 clinical program consisting
of two separate trials. The candidate is a proprietary orally inhaled
formulation of d...
|
|
MAP Pharmaceuticals Reports Positive Phase 2 Results for its Pediatric Asthma Drug Candidate
Feb 27, 2007
|
6.9 KB |
|
| |
MOUNTAIN VIEW, Calif., February 27 /PRNewswire/ -- MAP Pharmaceuticals, Inc. announced today that its Unit Dose Budesonide (UDB) drug candidate met its primary efficacy endpoints in a Phase 2 clinical trial. UDB is a proprietary nebulized formulation of budesonide for treatment of pediatric asthma.
The multicenter, randomized...
|
|
MAP Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Feb 1, 2007
|
4.2 KB |
|
| |
MOUNTAIN VIEW, Calif., February 1 /PRNewswire/ -- MAP Pharmaceuticals,
Inc., a privately-held biopharmaceutical company focused on developing
novel treatments for respiratory and CNS diseases, today announced
that it will present a company update at the Merrill Lynch Global
Pharmaceut...
|
|
MAP Pharmaceuticals to Present at the 25th Annual JP Morgan Healthcare Conference
Jan 4, 2007
|
4.2 KB |
|
| |
MOUNTAIN VIEW, Calif., January 4 /PRNewswire/ -- MAP Pharmaceuticals,
Inc., a privately-held, product based biopharmaceutical company
focused on developing novel treatments for respiratory and CNS diseases,
today announced that it will present a company update at the 25th
Annual JP Mo...
|
|
MAP Pharmaceuticals, Inc. to Present at the RBC Capital Markets Healthcare Conference
Dec 14, 2006
|
4.3 KB |
|
| |
MOUNTAIN VIEW, Calif., December 14 /PRNewswire/ -- MAP Pharmaceuticals,
Inc., a privately-held, product based biopharmaceutical company
focused on developing novel treatments for respiratory and CNS diseases,
today announced that it will take part in a group panel discussion
at the 20...
|
|
MAP Pharmaceuticals, Inc. to Present at the Rodman and Renshaw 8th Annual Healthcare Conference
Nov 8, 2006
|
4.2 KB |
|
| |
MOUNTAIN VIEW, Calif., November 8 /PRNewswire/ -- MAP Pharmaceuticals,
Inc., a privately-held, product based biopharmaceutical company
focused on developing novel treatments for respiratory and CNS diseases,
today announced that it will present a company update at the Rodman
and Rensh...
|
|
MAP Pharmaceuticals Appoints New Chief Financial Officer
Oct 12, 2006
|
5.0 KB |
|
| |
MOUNTAIN VIEW, Calif., Oct 12 /PRNewswire/ -- MAP Pharmaceuticals,
Inc. a leading developer of novel drug therapies, today announced
the appointment of Christopher Y. Chai to the position of Chief
Financial Officer.
Mr. Chai has spent over 15 years in the healthcare and banking
...
|
|
MAP Pharmaceuticals Appoints New Sr. Vice President of Corporate and Business Development
Oct 11, 2006
|
5.3 KB |
|
| |
MOUNTAIN VIEW, Calif., Oct 11 /PRNewswire/ -- MAP Pharmaceuticals,
a leading developer of novel drug therapies, today announced the
appointment of Tassos Gianakakos to the position of Sr. Vice President,
Corporate and Business Development.
Mr. Gianakakos brings with him a wealth ...
|
|
MAP Pharmaceuticals Announces Expansion at Corporate Headquarters
Oct 5, 2006
|
4.6 KB |
|
| |
MOUNTAIN VIEW, Calif., October 5 /PRNewswire/ -- MAP Pharmaceuticals,
Inc., a leading developer of novel inhaled drug therapies, today
announced the expansion of its facility at 2400 Bayshore Parkway
in Mountain View, California to accommodate the company's recent
and anticipated futu...
|
|
MAP Pharmaceuticals to Present at UBS Global Life Sciences Conference
Sep 26, 2006
|
4.2 KB |
|
| |
MOUNTAIN VIEW, Calif., September 26 /PRNewswire/ -- MAP Pharmaceuticals,
Inc., a leading developer of novel inhaled drug products and systems,
today announced that it will present a company update at the UBS
Global Life Sciences Conference which is being held September 25-28
at the Gr...
|
|
MAP Pharmaceuticals to Present at VentureWire's Health Care Innovations 2006 Conference
Sep 12, 2006
|
4.2 KB |
|
| |
MOUNTAIN VIEW, Calif., September 12 /PRNewswire/ -- MAP Pharmaceuticals,
Inc., a leading developer of novel inhaled drug products and systems,
today announced that it will present a company update at VentureWire's
Health Care Innovations 2006 conference which is being held September
1...
|
|
MAP Pharmaceuticals Initiates Phase 2 Clinical Trial in Patients With Migraine
Sep 5, 2006
|
7.0 KB |
|
| |
MOUNTAIN VIEW, Calif., September 5 /PRNewswire/ -- MAP Pharmaceuticals
announced today the initiation and first patient dosing of a Phase
2 clinical trial evaluating MAP0004 for the treatment of acute migraine
headaches. MAP0004 is a novel inhaled drug formulation of dihydroergotamine
...
|
|
MAP Pharmaceuticals Initiates Phase 2 Clinical Trial in Pediatric and Adolescent Patients With Asthma
Aug 2, 2006
|
5.7 KB |
|
| |
MOUNTAIN VIEW, Calif., August 2 /PRNewswire/ -- MAP Pharmaceuticals
announced today the initiation and first patient dosing of a Phase
2 clinical trial evaluating MAP0010. MAP0010 is a proprietary nebulized
formulation of budesonide for the inhalation treatment of asthma
...
|
|
MAP Pharmaceuticals Appoints New Program Directors
Jul 19, 2006
|
7.0 KB |
|
| |
MOUNTAIN VIEW, Calif., July 19 /PRNewswire/ -- MAP Pharmaceuticals,
a leading developer of novel inhaled drug products, today announced
the appointment of Scott W. Borland to the position of Tempo(TM)
DHE Program Director. MAP Pharmaceuticals also announced the appointment
of Paul S. ...
|
|
MAP and Xemplar Sign Exclusive Manufacturing Deal for Innovative Tempo(TM) Inhaler Products
May 17, 2006
|
7.4 KB |
|
| |
Mountain View, CA, and Fall River, MA, May 17, 2006 - MAP
Pharmaceuticals, Inc., a leading developer of novel inhaled drug
therapies, and Xemplar Pharmaceuticals LLC, a contract services
company developing inhalation products, today announced the signing
of an agreement under which Xe...
|
|
MAP Pharmaceuticals Closes $25.25 Million Series C Financing
Jan 25, 2006
|
5.0 KB |
|
| |
Mountain View, CA, January 25, 2006 - MAP Pharmaceuticals,
Inc., a leading developer of novel inhaled drug therapies, today
announced the closing of a $25.25 million Series C preferred stock
financing with several top-tier biotechnology investors. Proceeds
from this financing will be ...
|
|
Eiffel Technologies and MAP Pharmaceuticals Sign Development and Licensing Agreement for Multiple Inhaled Products
Sep 22, 2005
|
8.1 KB |
|
| |
Sydney, Australia and Mountain View, California, USA. September
22, 2005. - Eiffel Technologies Limited (ASX: EIF) and MAP
Pharmaceuticals, Inc. announced today that the companies have signed
a development and licensing agreement that provides MAP with the
exclusive right to apply Eif...
|
|
MAP Pharmaceuticals Announces Expanded Development Agreement With Elan Drug Technologies
Jul 27, 2005
|
8.2 KB |
|
| |
Mountain View, CA, July 27, 2005 - MAP Pharmaceuticals, Inc.
announced today that MAP and Elan Corporation, plc (NYSE:ELN) have
agreed to amend their previous agreement, signed in 2004, to seek
to apply Elan's proprietary NanoCrystal(R) technology to
defined inhalation therapies. MAP h...
|
|
MAP Pharmaceuticals Appoints Timothy S. Nelson as President and Chief Executive Officer
Apr 18, 2005
|
4.4 KB |
|
| |
Mountain View, CA, April 18, 2005 - MAP Pharmaceuticals,
Inc., a leading developer of novel inhaled drug products, today
announced the appointment of Timothy S. Nelson as the company's
new president and chief executive officer. Mr. Nelson will also
join the company's board of director...
|
|
MAP Pharmaceuticals Appoints New Vice President of Clinical and Regulatory Affairs
Mar 28, 2005
|
5.4 KB |
|
| |
Mountain View, CA, March 28, 2005 - MAP Pharmaceuticals,
Inc., a leading developer of novel inhaled drug products, today
announced the appointment of Stephen B. Shrewsbury, M.D., to the
position of Vice President, Clinical and Regulatory Affairs. In
this role, Dr. Shrewsbury will be r...
|
|
|
